We have shown that the plasma membrane Ca2+-ATPase (PMCA) seems to be involved in Ca2+ dysregulation associated with AD, because it is functionally inhibited by both Aβ and tau [31,32]. The gene discussed is MAPT; the disease is Alzheimer disease.